Based in Paris (France), ÓSKARE CAPITAL, has launched the first AIFM and ESG compatible fund with an investment focus on innovative companies and teams in the medical cannabinoid industry.
This pioneer investment fund which is AIFM domiciled in Dublin, Ireland will be investing principally in European companies and teams that are working with cannabinoids and the related infrastructure, and which are developing disruptive, science-led solutions and emerging technologies within this medical and healthcare sector.
Unlike many other funds, ÓSKARE CAPITAL will not be investing directly in opportunities related to the recreational cannabinoid market. Rather the fund will prioritize investment in development of medical and pharmaceutical products for which there is strong scientific rationale to utilize cannabinoids.
The fund will target its investments in a balanced portfolio of companies developing highly disruptive technologies, services and solutions with a focus on scientific innovations that lead to tangible outcomes in the wellness and medical sectors.
We aim to achieve high growth investments and returns by leveraging science and technology, finding, nurturing and incubating the most promising opportunities to create meaningful patient outcomes and to advance the medical cannabinoid sector.
Why Europe ?
Europe now enjoys the best regulatory environment for innovation and for research and development in medical and therapeutic cannabinoids. Europe’s legal medical cannabis sales in 2018 totalled €316 million and is expected to have high double-digit growth¹. With Europe’s current population of 743 million population and health care expenditure of €2.3 trillion, the expectation is that the European medical cannabis market by 2024 will be $2.8 billion and global medical cannabis market $15 billion by 2029.²
¹ Prohibition Partners, European Cannabis Report, London, UK, November 2019.
² Internal Data February 2020.
A Vast Frontier
With the global medical cannabis market estimated to grow in double digits over the next 10-15 years, the North-American market enabled innovation and gave a sense of what the future holds; errors made there can be avoided in Europe.